Mérieux Equity Partners (MxEP) has taken a majority stake in curea medical, a carve-out from McAirlaid’s, through its buyout fund Mérieux Participations 4 (MP4). The investment will fuel curea’s continued growth and innovation in advanced wound care, alongside an accelerated international expansion strategy.
As part of the transaction, McAirlaid’s and the management team – including CEO Andreas Bolz – will reinvest alongside MxEP.
Headquartered in Steinfurt, Germany, with operations in Heilbad Heiligenstadt, curea medical has built a strong presence in advanced wound dressings, serving homecare providers, hospitals, and pharmacies across Europe, with Germany as its core market. The company benefits from its proprietary SuperCore® superabsorbent technology, a market-leading innovation in exudate management, delivering superior absorption and retention versus conventional foam dressings.
Founded in 2010, curea medical has consistently achieved double-digit organic revenue growth.
The acquisition marks the tenth investment for MP4, MxEP’s latest private equity vehicle, which closed at approximately €570m, and represents its first transaction in Germany.
